ArticleJTCVS open2026
Local amiodarone delivery via an extracellular collagen matrix patch to reduce new-onset postoperative atrial fibrillation.
Article in JTCVS open, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objective: Systemic amiodarone is commonly used to treat new-onset postoperative atrial fibrillation (POAF) after cardiac surgery with risk for significant toxicity. This study explored the feasibility and safety of using an extracellular collagen matrix patch (CardiaMend, or the patch), aiming to deliver therapeutically relevant concentrations of amiodarone to atrial tissues whilst mitigating the systemic adverse effects related with intravenous or oral administration of amiodarone. Methods: The patch was saturated with amiodarone hydrochloride solution (50 mg/mL, Fresenius Kabi) and implanted in ovine and rat models for pericardial and epicardial repair for up to 28 days. Amiodarone concentrations were measured in atrial tissue, lungs, liver, and plasma. Histologic analysis assessed tissue response to the patch and amiodarone application. Results: Pharmacologically relevant amiodarone concentrations were detected in atrial and ventricular tissue within 3 to 7 days, correlating with the time window for the highest incidence of POAF. Importantly, during the same time, low or undetectable drug levels were observed in the lungs, liver, and systemic circulation. Histology showed no evidence of tissue damage, fibrosis, or exacerbated inflammation associated with the patch and amiodarone application in either model. Conclusions: These findings indicate that CardiaMend can deliver therapeutically relevant concentrations of amiodarone to atrial tissues while mitigating the systemic adverse effects related with intravenous or oral administration of amiodarone. This approach could present a promising strategy for POAF prevention. Future clinical trials would be valuable to determine whether these findings translate into an effective prophylaxis for reducing the rate of new-onset POAF in cardiac surgery patients.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.